May 7, 2020 / 12:53 PM / 25 days ago

BRIEF-Daiichi Sankyo Submits Supplemental New Drug Application For Trastuzumab Deruxtecan In Japan For Treatment Of Patients With HER2 Positive Metastatic Gastric Cancer

May 7 (Reuters) - Daiichi Sankyo Co Ltd:

* DAIICHI SANKYO SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR TRASTUZUMAB DERUXTECAN IN JAPAN FOR TREATMENT OF PATIENTS WITH HER2 POSITIVE METASTATIC GASTRIC CANCER

* DAIICHI SANKYO CO LTD - TRASTUZUMAB DERUXTECAN WILL RECEIVE AN EXPEDITED REVIEW TIME OF SIX MONTHS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below